US 12,251,423 B2
Method of effecting neuroprotection using soluble neuregulin isoforms
André Schrattenholz, Mainz (DE)
Assigned to Mind-NRG Sàrl, Geneva (CH)
Filed by Mind-NRG Sàrl, Geneva (CH)
Filed on Sep. 4, 2020, as Appl. No. 17/012,159.
Application 16/420,755 is a division of application No. 15/333,959, filed on Oct. 25, 2016, granted, now 10,350,269, issued on Jul. 16, 2019.
Application 14/271,617 is a division of application No. 12/742,983, abandoned, previously published as PCT/EP2008/009715, filed on Nov. 17, 2008.
Application 17/012,159 is a continuation of application No. 16/420,755, filed on May 23, 2019, granted, now 10,813,978.
Application 15/333,959 is a continuation of application No. 14/271,617, filed on May 7, 2014, abandoned.
Claims priority of provisional application 60/988,576, filed on Nov. 16, 2007.
Prior Publication US 2021/0077579 A1, Mar. 18, 2021
Int. Cl. A61P 25/18 (2006.01); A61K 31/5513 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); C07K 14/475 (2006.01); C07K 14/485 (2006.01)
CPC A61K 38/1883 (2013.01) [A61K 31/5513 (2013.01); A61K 38/1808 (2013.01); A61K 38/185 (2013.01); A61K 45/06 (2013.01); C07K 14/4756 (2013.01); C07K 14/485 (2013.01)] 11 Claims
 
1. A method of treating a subject suffering from schizophrenia, comprising intravenously administering to the subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β, wherein the recombinant soluble Type I Neuregulin-1 β isoform is the first 245, 246, 247, 248, 249, or 250 amino acids of Type I Neuregulin-1 β and is administered in an amount of about 400 ng/kg to about 600 ng/kg body weight of the subject to be treated.